drugset / Trial / NCT01809301
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Phase 1
Completed
20 enrolled
Cortria Corporation
PPD Development, LP · collabPharmena North America · collab
RandomizedCrossoverOpen-label
Summary
The objective of this study is to compare the absorption of a niacin metabolite (1-methylnicotinamide, 1-MNA) from TRIA-662 (1-methylnicotinamide chloride)relative to the production of 1-MNA from Niaspan. The 1-MNA information obtained from this study will be used to adjust the top dose of a planned TRIA-622 efficacy study.
Timeline
- Start
- 2013-03
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Niacin | Small molecule | 1000 mg | — |
| Subject | TRIGONELLAMIDE | Small molecule | 1000 mg | — |
Indications
No indication recorded.